TargetBeta
CD3E
CD3 epsilon subunit of T-cell receptor complex · also CD3epsilon, CD3-epsilon · CD molecules
84 programs in company-led studies act on CD3E, from 49 companies: 24 in phase 3, 5 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (60 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| linvoseltamabrule | Regeneron Pharmaceuticals | phase 4 | 1312 running | TNFRSF17 | NCIt |
| teclistamabrule | Johnson & Johnson | phase 4 | 1110 running | TNFRSF17 | NCIt |
| elranatamabrule | Pfizer | phase 4 | 159 running | TNFRSF17 | NCIt |
| blinatumomabrule | Amgen | phase 4 | 297 running | CD19 | ChEMBL |
| teplizumabrule | Sanofi | phase 4 | 92 running | – | ChEMBL |
| epcoritamabrule | Genmab | phase 3 | 1312 running | MS4A1 | ChEMBL |
| tarlatamabrule | Amgen | phase 3 | 1312 running | DLL3 | ChEMBL |
| Alveltamigrule | Suzhou Zelgen Biopharmaceuticals | phase 3 | 1111 running | DLL3 | NCIt |
| etentamig | AbbVie | phase 3 | 1111 running | TNFRSF17 | the company's pipeline |
| obrixtamig | Boehringer Ingelheim | phase 3 | 1111 running | DLL3 | the company's pipeline |
| surovatamig | AstraZeneca | phase 3 | 1010 running | CD19 | a judged reading |
| glofitamabrule | Hoffmann-La Roche | phase 3 | 139 running | MS4A1 | ChEMBL |
| Anti-CD19/CD3 Bispecific Antibody MK-1045 | Merck | phase 3 | 88 running | CD19 | a judged reading |
| mosunetuzumabrule | Hoffmann-La Roche | phase 3 | 147 running | MS4A1 | ChEMBL |
| cevostamab | Hoffmann-La Roche | phase 3 | 87 running | FCRL5 | a judged reading |
| ramantamig | Johnson & Johnson | phase 3 | 77 running | GPRC5D, TNFRSF17 | a judged reading |
| xaluritamigrule | Amgen | phase 3 | 77 running | STEAP1 | NCIt |
| odronextamabrule | Regeneron Pharmaceuticals | phase 3 | 86 running | MS4A1 | ChEMBL |
| GR1803rule | Chongqing Genrix Biopharmaceutical | phase 3 | 76 running | – | the studies' text |
| Anti-Claudin18.2/Anti-CD3 Bispecific Antibody QLS31905rule | Qilu Pharmaceutical | phase 3 | 65 running | CLDN18 | NCIt |
| CM336rule | Keymed Biosciences | phase 3 | 55 running | – | the studies' text |
| pasritamig | Johnson & Johnson | phase 3 | 55 running | KLK2 | a judged reading |
| TQB2825 | Sino Biopharmaceutical | phase 3 | 54 running | MS4A1 | the company's pipeline |
| Anti-CD3/Anti-BCMA Bispecific Antibody TQB2934 | Sino Biopharmaceutical | phase 3 | 44 running | TNFRSF17 | the company's pipeline |
| gocatamig | Merck | phase 3 | 44 running | DLL3 | a judged reading |
| GPRC5D/BCMA/CD3-targeting T-cell Engager IBI3003rule | Innovent Biologics | phase 3 | 44 running | GPRC5D, TNFRSF17 | NCIt |
| emaretamigrule | Astellas Pharma | phase 3 | 33 running | CLDN18 | NCIt |
| QLS4131rule | Qilu Pharmaceutical | phase 3 | 33 running | GPRC5D | the studies' text |
| QLS32015rule | Qilu Pharmaceutical | phase 3 | 22 running | GPRC5D | the studies' text |
| YK012rule | Excyte Biopharma | phase 2 | 55 running | CD19 | the studies' text |
| cizutamigrule | UCB | phase 2 | 52 running | TNFRSF17 | NCIt |
| vonsetamigrule | Regeneron Pharmaceuticals | phase 2 | 32 running | TNFRSF17 | NCIt |
| Anti-BCMA/CD38/CD3 Trispecific Antibody ABBV-2001 | AbbVie | phase 2 | 22 running | CD38, TNFRSF17 | the company's pipeline |
| Anti-CD20/Anti-CD3/Anti-CD8 Trispecific Antibody AZD5492 | AstraZeneca | phase 2 | 22 running | CD8A, MS4A1 | a judged reading |
| Anti-FLT3/CD3 Bispecific Antibody CLN-049rule | Cullinan Therapeutics | phase 2 | 22 running | FLT3 | NCIt |
| Anti-ROR1/Anti-CD3 Bispecific Antibody EMB-07rule | Shanghai EpimAb Biotherapeutics | phase 2 | 22 running | ROR1 | NCIt |
| GSK5926371 | GlaxoSmithKline | phase 2 | 22 running | CD19, MS4A1 | the company's pipeline |
| olsutamigrule | Regeneron Pharmaceuticals | phase 2 | 22 running | FOLH1 | NCIt |
| YKST02rule | Excyte Biopharma | phase 2 | 22 running | – | the studies' text |
| foralumabrule | Tiziana Life Sciences | phase 2 | 81 running | – | NCIt |
| Anti-Claudin18.2/Anti-CD3 Bispecific Antibody AZD5863 | AstraZeneca | phase 2 | 11 running | CLDN18 | a judged reading |
| Anti-GPC3 T Cell-engaging Antibody AZD9793 | AstraZeneca | phase 2 | 11 running | CD8A, GPC3 | a judged reading |
| Anti-PSMA/Anti-CD3 T-cell Engager GSK5458514rule | GlaxoSmithKline | phase 2 | 11 running | FOLH1 | NCIt |
| Anti-STEAP2/Anti-CD3/Anti-CD8 Trispecific Antibody AZD6621 | AstraZeneca | phase 2 | 11 running | CD8A, STEAP2 | a judged reading |
| MBS314 for Injectionrule | Beijing Mabworks Biotech | phase 2 | 11 running | GPRC5D | the studies' text |
| REGN17372rule | Regeneron Pharmaceuticals | phase 2 | 11 running | CD28, GPRC5D | the studies' text |
| REGN9220rule | Regeneron Pharmaceuticals | phase 2 | 11 running | CD22, MS4A1 | the studies' text |
| SHR-7787 | Jiangsu HengRui Medicine | phase 2 | 11 running | DLL3 | the company's pipeline |
| SOA101rule | Shine-On Biomedical | phase 2 | 11 running | – | the studies' text |
| VG712rule | Virogen Biotechnology | phase 2 | 11 running | – | the studies' text |
| VTRU200rule | Vitruviae | phase 2 | 11 running | – | the studies' text |
| Anti-CD19/Anti-CD3/Anti-CD28 Trispecific Antibody CC312rule | CytoCares | phase 1 | 44 running | CD19, CD28 | NCIt |
| Anti-CD19/CD3 T-cell Engaging Bispecific Antibody CLN-978rule | Cullinan Therapeutics | phase 1 | 43 running | CD19 | NCIt |
| Anti-CD19/Anti-CD3/Anti-CD2 Trispecific Antibody PIT565 | Novartis | phase 1 | 33 running | CD19, CD2 | the company's pipeline |
| Anti-CD79b/CD20/CD3 Trispecific Antibody JNJ-80948543rule | Johnson & Johnson | phase 1 | 33 running | MS4A1 | NCIt |
| Anti-CLDN6/CD3 Bispecific Antibody XmAb541rule | Xencor | phase 1 | 22 running | CLDN6 | NCIt |
| OM336rule | Lakefront Biotherapeutics NV | phase 1 | 22 running | – | the studies' text |
| Anti-TMEFF2/Anti-CD3 Bispecific Antibody JNJ-70218902rule | Johnson & Johnson | phase 1 | 21 running | TMEFF2 | NCIt |
| clesitamig | Hoffmann-La Roche | phase 1 | 21 running | DLL3, TNFRSF9 | a judged reading |
| Anti-B7-H7/Anti-CD3 Bispecific Antibody NPX372rule | NextPoint Therapeutics | phase 1 | 11 running | HHLA2 | NCIt |
| Anti-BAFF-R/Anti-CD3 Bispecific Antibody LY4152199rule | Eli Lilly | phase 1 | 11 running | TNFRSF13C | NCIt |
| Anti-CALRmut/Anti-CD3 Bispecific Antibody JNJ-88549968 | Johnson & Johnson | phase 1 | 11 running | CALR | a judged reading |
| Anti-CD24/Anti-CD3 Bispecific Antibody ONC-783rule | OncoC4 | phase 1 | 11 running | CD24 | NCIt |
| Anti-CD70/CD3 Bispecific Antibody INCA036873rule | Incyte | phase 1 | 11 running | CD70 | NCIt |
| Anti-CG1/Anti-CD3 Bispecific T-cell Engager CBX-250rule | Crossbow Therapeutics | phase 1 | 11 running | – | NCIt |
| Anti-CLDN6/Anti-CD3 Bispecific Antibody BGB-B455rule | BeOne Medicines | phase 1 | 11 running | CLDN6 | NCIt |
| Anti-ENPP3/Anti-CD3 Bispecific Antibody JNJ-87890387 | Johnson & Johnson | phase 1 | 11 running | ENPP3 | a judged reading |
| Anti-FRa/Anti-CD3 Bispecific TCE NTB-928rule | TeneoSeven | phase 1 | 11 running | FOLR1 | NCIt |
| Anti-HLA-A*02:01/p53 R175H Bispecific T-cell Engager CLSP-1025rule | Clasp Therapeutics | phase 1 | 11 running | TP53 | NCIt |
| Anti-LY6G6D/Anti-CD3 T-cell Engager CBI-1214rule | Cartography Biosciences | phase 1 | 11 running | LY6G6D | NCIt |
| Anti-mutCALR/Anti-CD3 Bispecific Antibody INCA035784rule | Incyte | phase 1 | 11 running | – | NCIt |
| Anti-PSMA/Anti-CD3 Dual-masked T-cell Engager JANX014rule | Janux Therapeutics | phase 1 | 11 running | FOLH1 | NCIt |
| Anti-TERT/Anti-CD3 T-cell Engager CBX-663rule | Crossbow Therapeutics | phase 1 | 11 running | TERT | NCIt |
| Anti-ULBP2/5/6/CD3/CD2 Trispecific T-cell Engager EVOLVE104rule | EvolveImmune United | phase 1 | 11 running | CD2, RAET1G, ULBP2 | NCIt |
| ATG-201rule | Antengene Biologics | phase 1 | 11 running | CD19 | the studies' text |
| EMB-15rule | Shanghai EpimAb Biotherapeutics | phase 1 | 11 running | ALPG, ALPP | the studies' text |
| HLX3901 | Fosun Pharma | phase 1 | 11 running | CD28, DLL3 | the company's pipeline |
| HLX3902 | Fosun Pharma | phase 1 | 11 running | CD28, STEAP1 | the company's pipeline |
| KGX105rule | Kangabio AUSTRALIA LTD PTY | phase 1 | 11 running | EGFR | the studies' text |
| KT501rule | Kali Therapeutics | phase 1 | 11 running | CD19 | the studies' text |
| KT502rule | Kali Therapeutics | phase 1 | 11 running | CD19 | the studies' text |
| LVV Expressing VSV Glycoprotein/Anti-CD3 scFv Containing Transgene Encoding for Anti-BCMA CAR KLN-1010rule | Kelonia Therapeutics | phase 1 | 11 running | TNFRSF17 | NCIt |
| TQB2029 | Sino Biopharmaceutical | phase 1 | 11 running | GPRC5D | the company's pipeline |
| Anti-B7-H6/Anti-CD3 Bispecific Antibody BI 765049rule | Boehringer Ingelheim | phase 1 | 30 running | NCR3LG1 | NCIt |
Also acted on by the same programs
Conditions their studies are in
- Multiple Myeloma, 20 programs
- Lupus Erythematosus, Systemic, 11 programs
- Lymphoma, Non-Hodgkin, 11 programs
- Prostatic Neoplasms, 8 programs
- Lymphoma, B-Cell, 7 programs
- Lymphoma, Large B-Cell, Diffuse, 7 programs
- Lymphoma, Follicular, 6 programs
- Arthritis, Rheumatoid, 5 programs
- Small Cell Lung Carcinoma, 5 programs
- Leukemia, Lymphocytic, Chronic, B-Cell, 4 programs
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Nov 18, 2026cevostamab · Hoffmann-La Roche · phase 3 · NCT05646836
- Dec 2026Alveltamig · Suzhou Zelgen Biopharmaceuticals · phase 3 · NCT06592638
- Dec 2026Anti-Claudin18.2/Anti-CD3 Bispecific Antibody QLS31905 · Qilu Pharmaceutical · phase 3 · NCT06942767
- Dec 2026QLS4131 · Qilu Pharmaceutical · phase 3 · NCT07001839
- Dec 2026YK012 · Excyte Biopharma · phase 2 · NCT06982729
- Dec 2026SHR-7787 · Jiangsu HengRui Medicine · phase 2 · NCT06605222
- Dec 2026Anti-CD19/CD3 T-cell Engaging Bispecific Antibody CLN-978 · Cullinan Therapeutics · phase 1 · NCT06613360
- Dec 2026OM336 · Lakefront Biotherapeutics NV · phase 1 · NCT07083960
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.